Tag: inspection readiness

How to Handle Suspected Fraud or Falsification Discovered During Inspections

November 21, 2025November 21, 2025 digi

How to Handle Suspected Fraud or Falsification Discovered During Inspections Step-by-Step Tutorial: Handling Suspected Fraud or Falsification Discovered During GMP Inspections Suspected fraud or falsification during a GMP inspection or GMP audit represents one of the most critical challenges a pharmaceutical company can face. Regulatory bodies such as the FDA, EMA, MHRA, and PIC/S authorities…

FDA 483, Warning Letters & GMP Inspections

Coordinating With Legal and Compliance Teams on Serious GMP Findings

November 21, 2025November 21, 2025 digi

Coordinating With Legal and Compliance Teams on Serious GMP Findings Effective Coordination With Legal and Compliance Teams on Serious GMP Findings In pharmaceutical manufacturing and quality management, the occurrence of serious findings during a GMP inspection or GMP audit demands a coordinated, multi-disciplinary response. Regulatory authorities across the US, UK, and EU rely heavily on…

FDA 483, Warning Letters & GMP Inspections

Communicating GMP Issues to Customers After a Regulatory Inspection

November 21, 2025November 21, 2025 digi

Communicating GMP Issues to Customers After a Regulatory Inspection Effective Communication of GMP Issues to Customers Following Regulatory Inspections Pharmaceutical manufacturers operating within the US, UK, and EU regulatory framework must adhere strictly to Good Manufacturing Practice (GMP) principles. Regulatory inspections, including FDA 483 observations, are pivotal in assessing compliance status. Occasionally, inspections result in…

FDA 483, Warning Letters & GMP Inspections

Presenting Process Validation and CPV Evidence to Convince Inspectors

November 21, 2025November 21, 2025 digi

Presenting Process Validation and CPV Evidence to Convince Inspectors Step-by-Step Guide to Presenting Process Validation and CPV Evidence Effectively During GMP Inspections For pharmaceutical manufacturers operating under FDA, EMA, MHRA, or other global regulatory expectations, effective presentation of process validation and Continued Process Verification (CPV) evidence during a GMP inspection or GMP audit is crucial….

FDA 483, Warning Letters & GMP Inspections

Explaining Complex Manufacturing Flows Clearly to GMP Auditors

November 21, 2025November 21, 2025 digi

Explaining Complex Manufacturing Flows Clearly to GMP Auditors How to Explain Complex Manufacturing Flows Clearly During a GMP Audit Pharmaceutical manufacturing operations often involve intricate processes, multi-step production sequences, and integrated control measures that build the foundation for compliant drug product and drug substance manufacture. When a regulatory GMP inspection takes place, effectively communicating the…

FDA 483, Warning Letters & GMP Inspections

Handling Questions on Legacy Equipment and Obsolete Documentation

November 21, 2025November 21, 2025 digi

Handling Questions on Legacy Equipment and Obsolete Documentation Step-by-Step Guide to Handling Questions on Legacy Equipment and Obsolete Documentation During GMP Audits Pharmaceutical manufacturers in the US, UK, and EU routinely face challenges during GMP inspections and audits related to legacy equipment and obsolete documentation. Regulatory agencies including FDA, EMA, MHRA, and PIC/S consistently focus…

FDA 483, Warning Letters & GMP Inspections

Explaining Historical GMP Decisions Without Triggering New Concerns

November 21, 2025November 21, 2025 digi

Explaining Historical GMP Decisions Without Triggering New Concerns How to Explain Historical GMP Decisions Without Triggering New Concerns: A Step-by-Step Guide for Pharma Professionals Pharmaceutical companies operating within the US, UK, and EU markets must be prepared to navigate rigorous GMP inspections, including responding effectively to observations found in FDA 483 forms and similar regulatory…

FDA 483, Warning Letters & GMP Inspections

Using Quality Risk Management Output to Defend GMP Choices

November 21, 2025November 21, 2025 digi

Using Quality Risk Management Output to Defend GMP Choices Leveraging Quality Risk Management Output to Defend GMP Decisions During Inspections For pharmaceutical professionals operating within the US, UK, and EU regulatory frameworks, understanding how to effectively utilize quality risk management (QRM) outputs to defend Good Manufacturing Practice (GMP) decisions is fundamental to achieving inspection readiness…

FDA 483, Warning Letters & GMP Inspections

Proactively Communicating GMP Progress to Regulators After a Warning Letter

November 21, 2025November 21, 2025 digi

Proactively Communicating GMP Progress to Regulators After a Warning Letter Effective Strategies for Proactively Communicating GMP Progress to Regulators After a Warning Letter The receipt of a warning letter following a GMP inspection or FDA 483 observation is a critical juncture for pharmaceutical manufacturers. This formal communication from regulatory authorities signals significant compliance deficiencies that…

FDA 483, Warning Letters & GMP Inspections

Preparing for Re-Inspection and Verification of GMP CAPA

November 21, 2025November 21, 2025 digi

Preparing for Re-Inspection and Verification of GMP CAPA Step-by-Step Guide to Preparing for Re-Inspection and Verification of GMP CAPA Pharmaceutical manufacturers operating under the regulatory frameworks of the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and other global authorities must navigate complex…

FDA 483, Warning Letters & GMP Inspections